Evaluation of RO7276389 Monotherapy and Combination with Cobimetinib in BRAF-V600 Mutation-Positive Advanced Solid Tumors or Melanoma with CNS Metastases

The primary objective of this study is to evaluate the **safety** and **pharmacokinetics** of RO7276389, both as a monotherapy and in combination with **cobimetinib**, in participants diagnosed with **BRAF-V600 mutation-positive advanced solid tumors** or **BRAF-V600 mutation-positive melanoma** with or without central nervous system metastases. This evaluation is clinically relevant as it aims to determine the tolerability and appropriate dosing of RO7276389, which could potentially lead to improved therapeutic strategies for these conditions. The study also seeks to assess the preliminary clinical activity of the treatment regimen, which is crucial for understanding its potential efficacy in managing these challenging oncological conditions.

The clinical trial involves a total of **67 participants** diagnosed with **BRAF-V600 Mutation-Positive Advanced Solid Tumor** or **BRAF-V600 Mutation-Positive Melanoma**, with or without central nervous system metastases. The study population includes both male and female subjects, encompassing an age range that corresponds to categories 3 and 4, which typically include adults and older adults. Participants were selected based on their health status, specifically focusing on those with the aforementioned medical conditions. The trial includes a vulnerable population, indicating that special considerations are in place for the protection of these individuals. Lifestyle factors such as diet, physical activity, and habits were not specified by the sponsor. The selection process and specific inclusion or exclusion criteria were not detailed in the provided data.

The clinical trial is designed to evaluate the **safety**, pharmacokinetics, and preliminary clinical activity of RO7276389, both as a monotherapy and in combination with Cobimetinib, in participants diagnosed with **BRAF-V600 mutation-positive advanced solid tumors** or **BRAF-V600 mutation-positive melanoma** with or without central nervous system metastases. This trial is structured as a Phase 1 study, which typically focuses on assessing the safety and dosage of the investigational drug. The trial is expected to run from March 7, 2022, to December 20, 2027, providing a comprehensive evaluation period for the investigational treatments.

The trial employs a randomized, double-blind, controlled design to ensure unbiased results and to maintain the integrity of the data collected. Participants will be randomly assigned to receive either the investigational drug or a control, with neither the participants nor the investigators aware of the group assignments. This methodology is crucial in minimizing bias and ensuring the reliability of the trial outcomes.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on specific inclusion and exclusion criteria. Following successful screening, participants will enter the treatment phase, during which they will attend regular follow-up visits. These visits are designed to monitor the participants' health, assess the pharmacokinetics of the drug, and evaluate any adverse effects. The end-of-study visit will conclude the trial for each participant, during which final assessments will be conducted to gather comprehensive data on the investigational drug's efficacy and safety.

The expected length of participant involvement in the trial will vary depending on individual response to the treatment and the occurrence of any adverse events. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with the study protocol, or withdraw consent. The trial's design and procedures are meticulously planned to ensure the collection of high-quality data while prioritizing participant safety and well-being.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Consequently, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included. The absence of these details precludes a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an initial investigation into the safety and potential efficacy of the intervention. The estimated recruitment start date was March 7, 2022, with an anticipated completion by December 20, 2027. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often focus on safety and pharmacokinetics, with preliminary efficacy assessments potentially included. The trial will likely involve systematic data collection and analysis at predetermined intervals to evaluate the intervention's impact. The absence of detailed endpoints suggests that efficacy assessments may be exploratory, focusing on identifying any signals of therapeutic benefit. The trial's methodology will adhere to rigorous standards to ensure the reliability and validity of the findings.